TY - JOUR
T1 - Sarcopenia
T2 - Revised European consensus on definition and diagnosis
AU - Cruz-Jentoft, Alfonso J.
AU - Bahat, Gülistan
AU - Bauer, Jürgen
AU - Boirie, Yves
AU - Bruyère, Olivier
AU - Cederholm, Tommy
AU - Cooper, Cyrus
AU - Landi, Francesco
AU - Rolland, Yves
AU - Sayer, Avan Aihie
AU - Schneider, Stéphane M.
AU - Sieber, Cornel C.
AU - Topinkova, Eva
AU - Vandewoude, Maurits
AU - Visser, Marjolein
AU - Zamboni, Mauro
AU - Bautmans, Ivan
AU - Baeyens, Jean Pierre
AU - Cesari, Matteo
AU - Cherubini, Antonio
AU - Kanis, John
AU - Maggio, Marcello
AU - Martin, Finbarr
AU - Michel, Jean Pierre
AU - Pitkala, Kaisu
AU - Reginster, Jean Yves
AU - Rizzoli, René
AU - Sánchez-Rodríguez, Dolores
AU - Schols, Jos
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings. Objectives to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia. Recommendations sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia. Conclusions EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.
AB - Background in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings. Objectives to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia. Recommendations sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia. Conclusions EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.
KW - EWGSOP2
KW - muscle assessment
KW - muscle strength
KW - older people
KW - physical performance
KW - sarcopenia
UR - http://www.scopus.com/inward/record.url?scp=85059199520&partnerID=8YFLogxK
U2 - 10.1093/ageing/afy169
DO - 10.1093/ageing/afy169
M3 - Scientific review
C2 - 30312372
AN - SCOPUS:85059199520
VL - 48
SP - 16
EP - 31
JO - Age and Ageing
JF - Age and Ageing
SN - 0002-0729
IS - 1
ER -